Physician profile
Ora Charm
NPI 1366992836
$1,394.78
in general payments reported to CMS, 2019-2025
27 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $294 · 2023: $341 · 2024: $304 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $191.31 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $172.20 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.81 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.27 | 2025 | Caplyta |
| Novo Nordisk INC | $81.29 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Agile Therapeutics, INC. | $73.58 | 2021-2023 | Twirla |
| Lilly USA, LLC | $66.65 | 2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $60.24 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $58.63 | 2022 | |
| Exeltis, USA INC. | $41.66 | 2021-2023 | Nuvessa |
| Scynexis, INC. | $37.75 | 2022 | |
| Amgen INC. | $37.28 | 2024 | Repatha, Otezla |
| Dexcom, INC. | $35.82 | 2024 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $30.19 | 2021-2023 | Balcoltra |
| Astellas Pharma US INC | $28.33 | 2025 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.46 | 2024 | Xarelto |
| Evofem Biosciences, INC. | $24.05 | 2022 | |
| Hologic Sales and Service, LLC | $20.55 | 2023 | Thinprep 2000 Processor, Aptima |
| Astrazeneca Pharmaceuticals LP | $18.96 | 2024 | |
| Daiichi Sankyo INC. | $17.80 | 2021 | |
| Organon LLC | $17.52 | 2023 | |
| Coopersurgical, INC. | $17.25 | 2021 | |
| Axonics, INC. | $13.79 | 2023 | Axonics |
| Mylan Pharmaceuticals INC. | $13.79 | 2022 | |
| Myovant Sciences INC. | $13.24 | 2021 | |
| Merck Sharp & Dohme LLC | $12.75 | 2023 | Gardasil 9 |
| Ascend Therapeutics US, LLC | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ora Charm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.